5-Hydroxytryptophan in Friedreich’s Ataxia

Abstract

The effect of the levorotatory form of 5-hydroxytryptophan (approx 1 gm/day/orally) on cerebellar symptoms in 26 patients with Friedreich’s ataxia was evaluated in a double-blind drug-placebo study by the Ataxia Research Center, Hopital Neurologique, Lyon and 11 other research hospitals in France.

Keywords

• 5-hydroxytryptophan
• cerebellar symptoms
• friedreich’s ataxia